Comparative Clinical Study of Unani Poly Pharmaceutical Formulations in Fart-e-Tadassum-Fid-Dam (hyper-lipidaemia)

Fart-e-Tadassum-Fid-Dam (Hyper-lipidaemia) one of the major risk factors for the cardiovascular disease is not a single condition, but encompasses a wide range of disorders characterized by excess of fatty (lipid) substances in the blood due to metabolic derangement. The burden of cardiovascular disease (CVD) in the world is enormous and is constantly growing, the majority of which dwell in developing countries (Beaghole and yach, 2003; Mbewu, 1998). In 2002 it was estimated that 29 percent of deaths worldwide (16.7 million deaths) were due to CVD and that 43 percent of global morbidity and mortality, measured in disability-adjusted life years (DALYs), was caused by Cardiovascular disease (WHO, 2002). Furthermore, 78 percent of global mortality and 86 percent of mortality and morbidity due tocardiovascular disease occurs in developing countries. By 2020 it is estimated that Cardiovascular diseases will become the leading cause of the global health burden, accounting to 73 percent of total global mortality and 56 percent of total morbidity Murray and Lopez, 1996; Reddy and Yusuf, 1998

The present paper deals with comparative efficacy among Luk-e-Maghsool, combination of Sandarus with Luk-e-Maghsool and Sikanjbeensada in Fart-e-Tadassum Fid Dam (hyper-lipidaemia). The comparative study showed that Luke-Maghsool (study-1) has good results than Luk-e-Maghsool with Sandarus (study-2) and SikanjbeenSada (study-3) on biochemical parameters. Luk-e-Maghsool with Sandarus and SikanjbeenSada has similar efficacy on clinical parameters. Luk-e-Maghsool with Sandarus has better results on clinical parameters than Luk-e-Maghsool while SikanjbeenSada has similarity with study-2 on clinical parameters but has better results than both.